Pancreatic Cancer Global Clinical Trials Review, H1, 2016

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: May 01, 2016 Report Code: GDHC3415CTIDB-ST

Select Item

GlobalData's clinical trial report, “Pancreatic Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Pancreatic Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Pancreatic Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

F. Hoffmann-La Roche Ltd.
Novartis AG
Pfizer Inc.
Celgene Corporation
Sanofi
AstraZeneca Plc
Eli Lilly and Company
Merck & Co.
Inc.
Otsuka Holdings Co.
Ltd.
AbbVie Inc.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Report Guidance 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14

Top Five Countries Contributing to Clinical Trials in Central and South America 15

Clinical Trials by G7 Countries: Proportion of Pancreatic Cancer to Oncology Clinical Trials 16

Clinical Trials by Phase in G7 Countries 17

Clinical Trials in G7 Countries by Trial Status 18

Clinical Trials by E7 Countries: Proportion of Pancreatic Cancer to Oncology Clinical Trials 20

Clinical Trials by Phase in E7 Countries 21

Clinical Trials in E7 Countries by Trial Status 22

Clinical Trials by Phase 23

In Progress Trials by Phase 24

Clinical Trials by Trial Status 25

Clinical Trials by End Point Status 27

Subjects Recruited Over a Period of Time 28

Clinical Trials by Sponsor Type 29

Prominent Sponsors 30

Top Companies Participating in Pancreatic Cancer Therapeutics Clinical Trials 32

Prominent Drugs 34

Latest Clinical Trials News on Pancreatic Cancer 35

May 18, 2016: Lilly to present data on TGFß small-molecule kinase inhibitor galunisertib at ASCO 35

May 10, 2016: First Dosing of Pfizer DART Candidate in Phase 1 Study Triggers Milestone Payment to MacroGenics 35

May 09, 2016: NewLink Genetics Announces Results from Phase 3 IMPRESS Trial of Algenpantucel-L for Patients with Resected Pancreatic Cancer 36

May 05, 2016: PharmaCyte Biotech Clears Major Milestone on Path to FDA Clinical Trial 36

Apr 27, 2016: BERG Initiates Phase II Combination Trial Of BPM 31510 And Gemcitabine In Patients With Pancreatic Cancer 37

Apr 20, 2016: ARMO BioSciences Announces AM0010 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting in June 2016 38

Apr 20, 2016: Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin at the AACR Annual Meeting 2016 38

Apr 20, 2016: OncoMed Presents Biomarker Research for Vantictumab at the AACR Annual Meeting 2016 39

Apr 19, 2016: New class of small molecule drug, SI-2, has potential for improving cancer treatment 39

Apr 18, 2016: Halozyme Expands Oncology Pipeline With PEG-ADA2 Compound Designed For Activity In The Tumor Microenvironment 40

Apr 18, 2016: BERG Announces BPM31510 Data Presentations At 2016 AACR Annual Meeting 40

Apr 14, 2016: Asana BioSciences, to Provide First Presentation of Pre-Clinical Data on its Novel ERK 1/2 Inhibitor Program at the American Association for Cancer Research Annual Meeting 41

Apr 13, 2016: Celprogen provides an update on cancer compound CEP1430 41

Apr 13, 2016: Celprogen provides an update on cancer compound CEP1507 42

Apr 06, 2016: PharmaCyte Biotech's CEO Explains How New Clinical Trial Design Changed the GMP Certification Process 42

Apr 05, 2016: Silence Therapeutics: Atu027 update 43

Apr 05, 2016: CHK1 inhibitor CCT245737 Approved for Clinical Trials in Cancer Patients 43

Mar 31, 2016: PharmaCyte Biotech Finalizes Design of Pancreatic Cancer Clinical Trial and Identifies Trial Sites under Consideration 43

Mar 30, 2016: Verastem Announces Presentation of Scientific Data Supporting FAK Inhibition in Combination with Immunotherapy at the Keystone Symposium on Cancer Pathophysiology 44

Mar 24, 2016: Mirati Therapeutics To Present Mocetinostat Preclinical Data At 2016 American Association For Cancer Research Annual Meeting 45

Mar 22, 2016: CytRx to Present New Data Using Its Proprietary LADR Technology at the 2016 American Association for Cancer Research Annual Meeting 45

Mar 21, 2016: MabVax Therapeutics Initiates Phase I Trial of HuMab-5B1 for Treatment of Pancreatic Cancer 45

Mar 17, 2016: GlycoMimetics to Present New Preclinical Data on Its E-selectin-CXCR4 Dual Antagonist at AACR Annual Meeting 2016 46

Mar 17, 2016: Celldex Therapeutics to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2016 46

Mar 07, 2016: Data from MacroGenics’ Preclinical Studies of MGD009 Presented at Keystone Symposia’s Antibodies as Drugs (X2) Conference 47

Mar 02, 2016: Propanc Confirms PRP Response to Broad Range of Cancer Indications; Sets Date for Scientific Advice Meeting with UK Regulators 48

Feb 24, 2016: PharmaCyte Biotech on Schedule for 2016 Cancer Clinical Trial in Pancreatic Cancer 48

Feb 22, 2016: PharmaCyte Biotech Issues Update on Preparations for Its Pancreatic Cancer Clinical Trial 49

Feb 22, 2016: OncoQR ML Pancreatic Cancer Vaccine TYG100 Induces Clinically Relevant Immune Response Within Just 2 Weeks After Single Vaccination 50

Clinical Trial Profile Snapshots 52

Appendix 1682

Abbreviations 1682

Definitions 1682

Research Methodology 1683

Secondary Research 1683

About GlobalData 1684

Contact Us 1684

Disclaimer 1684

Source 1685

Table

Pancreatic Cancer Therapeutics, Global, Clinical Trials by Region, 2016* 7

Pancreatic Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 10

Pancreatic Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 11

Pancreatic Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 12

Pancreatic Cancer Therapeutics Clinical Trials, North America, Top Countries, 2016* 13

Pancreatic Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 14

Pancreatic Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 15

Proportion of Pancreatic Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 16

Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17

Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18

Proportion of Pancreatic Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 20

Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 21

Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 22

Pancreatic Cancer Therapeutics, Global, Clinical Trials by Phase, 2016* 23

Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 24

Pancreatic Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 25

Pancreatic Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 27

Pancreatic Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 28

Pancreatic Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 29

Pancreatic Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 30

Pancreatic Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 32

Pancreatic Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 34

Figures

Pancreatic Cancer Therapeutics, Global, Clinical Trials by Region (%), 2016* 7

Pancreatic Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 10

Pancreatic Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 11

Pancreatic Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 12

Pancreatic Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 13

Pancreatic Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 14

Pancreatic Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 15

Proportion of Pancreatic Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 16

Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17

Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18

Proportion of Pancreatic Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 20

Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 21

Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 22

Pancreatic Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2016* 23

Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 24

Pancreatic Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 25

Pancreatic Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 27

Pancreatic Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 28

Pancreatic Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 29

Pancreatic Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 30

Pancreatic Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 32

Pancreatic Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 34

GlobalData Methodology 1683

Frequently asked questions

Pancreatic Cancer Global Clinical Trials Review, H1, 2016 standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Pharmaceuticals
New
Borderline Personality Disorder (BPD) Clinical Trial Analysis by Phase, Trial…
$2,500 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Pancreatic Cancer Global Clinical Trials Review, H1, 2016 in real time.

  • Access a live Pancreatic Cancer Global Clinical Trials Review, H1, 2016 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more